Evidence map›Paper›PMID 19375665›Full record

ReviewThe Lancet. Neurology2009

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Matthew N Meriggioli, Donald B Sanders

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 307 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
307citing papers in PubMed, 11 pooled it
27.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

307 citing papers in PubMed, 11 syntheses or guidelines pooled it, 870 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. The associations of HLA-DRB1 gene polymorphisms with late-onset myasthenia gravis: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

247 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Matthew N MeriggioliDepartment of Neurology and Rehabilitation, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA. mmerig@uic.edu
Donald B Sanders
Duke Medical Center · USUniversity of Illinois Chicago · US

Funding

Immunoregulation of Experimental Autoimmune Myasthenia GravisK08NS058800 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MERIGGIOLI, MATTHEW NICHOLAS · 2007 to 2011
$886k
NINDS NIH HHS K08 NS058800NINDS NIH HHS K08NS058800-02
6 · The paper itself

Abstract

Acquired myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction in which patients experience fluctuating skeletal muscle weakness that often affects selected muscle groups preferentially. The target of the autoimmune attack in most cases is the skeletal muscle acetylcholine receptor (AChR), but in others, non-AChR components of the neuromuscular junction, such as the muscle-specific receptor tyrosine kinase, are targeted. The pathophysiological result is muscle endplate dysfunction and consequent fatigable muscle weakness. Clinical presentations vary substantially, both for anti-AChR positive and negative MG, and accurate diagnosis and selection of effective treatment depends on recognition of less typical as well as classic disease phenotypes. Accumulating evidence suggests that clinical MG subgroups might respond differently to treatment. In this Review, we provide current information about the epidemiology, immunopathogenesis, clinical presentations, diagnosis, and treatment of MG, including emerging therapeutic strategies.

Indexed as

Myasthenia GravisAdrenal Cortex HormonesAge FactorsAge of OnsetCholinesterase InhibitorsFemaleHumansImmunosuppressive AgentsImmunotherapyMaleNeuroimmunomodulationNeuromuscular JunctionReceptor Protein-Tyrosine KinasesReceptors, CholinergicSex FactorsThymectomyAdrenal Cortex HormonesCholinesterase InhibitorsImmunosuppressive AgentsMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, Cholinergic

Identifiers

PMID19375665
PMCPMC2730933
OpenAlexW2154803724

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.